

Ofrecer respuestas para la EPOC (Enfermedad pulmonar obstructiva crónica): Estrategias prácticas para mejorar el diagnóstico temprano y el tratamiento centrado en el paciente en atención primaria – Exposición del caso #2

Referencias

Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). *Eur Respir J*. 2015;45(4):969-979.

Calverley PMA, de la Hoz A, Xue W, et al. COPD maintenance therapy with tiotropium/olodaterol compared with tiotropium: an analysis in the absence of additional ICS therapy. *COPD*. 2020;17(5):477-484.

GOLD. 2022 GOLD reports. Accessed September 2022. <https://goldcopd.org/2022-gold-reports-2/>

Ichinose M, Nishimura M, Akimoto M, et al. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study. *Int J Chron Obstruct Pulmon Dis*. 2018;13:2147-2156.

IPCRG. Appropriate use and withdrawal of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD). May 2020. Accessed September 2022. <https://www.ipcr.org/sites/ipcr/files/content/attachments/2020-06-02/IPCRG%20DH6%20ICS%20COPD%20Rev%20May20.pdf>

Lavorini F, Janson C, Braido F, et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. *Ther Adv Respir Dis*. 2019;13:1753466619884532.

Lipari M, Kale-Pradhan PB, Wilhelm SM. Dual- versus mono-bronchodilator therapy in moderate to severe COPD: a meta-analysis. *Ann Pharmacother*. 2020;54(12):1232-1242.

Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respir Res*. 2019;20(1):238.

NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Accessed September 2022. <https://www.nice.org.uk/guidance/ng115>

Roche N, Devillier P, Berger P, et al. Individual trajectory-based care for COPD: getting closer, but not there yet. *ERJ Open Res*. 2021;7(4):00451-02021.

Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. *Respir Res*. 2016;17(1):73.

Singh D, Miravitlles M, Vogelmeier CF. Chronic obstructive pulmonary disease individualized therapy: tailored approach to symptom management. *Adv Ther.* 2016;34:281-299.

Singh D, Donohue JF, Boucot IH, et al. Future concepts in bronchodilation for COPD: dual- versus monotherapy. *Eur Respir Rev.* 2021;30(160):210023.

Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. *Lancet Respir Med.* 2013;1(3):199-209.

Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/olodaterol decreases exacerbation rates compared with tiotropium in a range of patients with copd: pooled analysis of the TONADO(®)/DYNAGITO(®) trials. *Adv Ther.* 2020;37(10):4266-4279.